Epidermal Growth Factor Removal or Tyrphostin AG1478 Treatment Reduces Goblet Cells & Mucus Secretion of Epithelial Cells from Asthmatic Children Using the Air-Liquid Interface Model


Autoria(s): Parker, Jeremy C; Douglas, Isobel; Bell, Jennifer; Comer, David; Bailie, Keith; Skibinski, Grzegorz; Heaney, Liam G.; Shields, Michael D.
Data(s)

09/06/2015

Resumo

<p>RATIONALE: Epithelial remodelling in asthma is characterised by goblet cell hyperplasia and mucus hypersecretion for which no therapies exist. Differentiated bronchial air-liquid interface cultures from asthmatic children display high goblet cell numbers. Epidermal growth factor and its receptor have been implicated in goblet cell hyperplasia.</p><p>OBJECTIVES: We hypothesised that EGF removal or tyrphostin AG1478 treatment of differentiating air-liquid interface cultures from asthmatic children would result in a reduction of epithelial goblet cells and mucus secretion.</p><p>METHODS: In Aim 1 primary bronchial epithelial cells from non-asthmatic (n = 5) and asthmatic (n = 5) children were differentiated under EGF-positive (10ng/ml EGF) and EGF-negative culture conditions for 28 days. In Aim 2, cultures from a further group of asthmatic children (n = 5) were grown under tyrphostin AG1478, a tyrosine kinase inhibitor, conditions. All cultures were analysed for epithelial resistance, markers of differentiation using immunocytochemistry, ELISA for MUC5AC mucin secretion and qPCR for MUC5AC mRNA.</p><p>RESULTS: In cultures from asthmatic children the goblet cell number was reduced in the EGF negative group (p = 0.01). Tyrphostin AG1478 treatment of cultures from asthmatic children had significant reductions in goblet cells at 0.2μg/ml (p = 0.03) and 2μg/ml (p = 0.003) as well as mucus secretion at 2μg/ml (p = 0.04).</p><p>CONCLUSIONS: We have shown in this preliminary study that through EGF removal and tyrphostin AG1478 treatment the goblet cell number and mucus hypersecretion in differentiating air-liquid interface cultures from asthmatic children is significantly reduced. This further highlights the epidermal growth factor receptor as a potential therapeutic target to inhibit goblet cell hyperplasia and mucus hypersecretion in asthma.</p>

Formato

application/pdf

Identificador

http://pure.qub.ac.uk/portal/en/publications/epidermal-growth-factor-removal-or-tyrphostin-ag1478-treatment-reduces-goblet-cells--mucus-secretion-of-epithelial-cells-from-asthmatic-children-using-the-airliquid-interface-model(3a4c24ee-c0b7-4518-add5-106e4c81f071).html

http://dx.doi.org/10.1371/journal.pone.0129546

http://pure.qub.ac.uk/ws/files/15904680/plosone_0129546.pdf

Idioma(s)

eng

Direitos

info:eu-repo/semantics/openAccess

Fonte

Parker , J C , Douglas , I , Bell , J , Comer , D , Bailie , K , Skibinski , G , Heaney , L G & Shields , M D 2015 , ' Epidermal Growth Factor Removal or Tyrphostin AG1478 Treatment Reduces Goblet Cells & Mucus Secretion of Epithelial Cells from Asthmatic Children Using the Air-Liquid Interface Model ' PloS one , vol 10 , no. 6 , e0129546 . DOI: 10.1371/journal.pone.0129546

Tipo

article